A risk score for device infection, conflicts of interest, the Fragility Index, rhythm vs rate control for AF in HFpEF, and year-end highlights are discussed by John Mandrola, MD, in this week's podcast.

The EXCEL trial controversy, and Dr John Mandrola's experience with vernakalant at FDA are the topics covered in this week's podcast.

Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week's podcast.

Highlights from the 2019 AHA meeting are analyzed by Dr John Mandrola in this week's podcast.

Interruption of oral anticoagulation, marijuana and stroke, ORBITA substudy, ISCHEMIA medical therapy targets, and more on AHA are the topics discussed by Dr. John Mandrola in this week's podcast.

Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week's podcast.

Mortality after AF ablation, cardiac rehab programs, hypertrophic cardiomyopathy, and clinician wellness are the topics Dr. John Mandrola discusses in this week's podcast.

AF after TAVR, opioids after cardiac devices, hypertension in black adults, and post-cardiac surgery AF are the topics Dr John Mandrola discusses in this week's podcast.

The Nobel Prize, more on the EXCEL trial, the costs of cardiac tests, familial hypercholesterolemia, and burnout are the topics discussed by Dr John Mandrola in this week's podcast.

Left main PCI vs CABG trials and TAVR vs SAVR—in this week's podcast, Dr John Mandrola takes a deeper dive.